Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 6Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Advanced Gastric Cancer 1

Interventions

Cisplatin 22Radiotherapy, Intensity-Modulated 12Fluorouracil 9Gemcitabine 7Docetaxel 7Cetuximab 5Capecitabine 5pembrolizumab 4nimotuzumab 3nedaplatin 3Radiotherapy 3Radiation 3Carboplatin 3toripalimab 2spartalizumab 2camrelizumab 2anlotinib 2Quality of Life 2Protons 2Paclitaxel 2Nivolumab 2Dexamethasone 2Chemoradiotherapy 2tislelizumab 1raltitrexed 1penpulimab 1icotinib 1fosaprepitant 1famitinib 1endostar protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Carcinoma × endostar protein × Clear all
NCT02237924 2022-02-14

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

First Affiliated Hospital of Guangxi Medical University

Phase 2 Completed
120 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡